Bitcoin price today: hits record high over $124k on rate cut bets, corporate cheer
Benjamin Halladay, the Chief Financial Officer of Esperion Therapeutics, Inc. (NASDAQ:ESPR), recently sold 3,535 shares of the company’s common stock. The sale, which took place on March 18, 2025, was executed at a price of approximately $1.483 per share, amounting to a total transaction value of $5,242. The stock has since risen to $1.67, though it remains down 28% year-to-date. According to InvestingPro analysis, the company maintains a market capitalization of $332 million. Following this transaction, Halladay retains ownership of 481,710 shares in the company. The shares were sold to satisfy tax obligations on vested restricted stock units. While the company faces challenges with a significant debt burden of $591 million, InvestingPro data shows strong revenue growth of 186% in the last twelve months. Discover more insights and 12+ additional ProTips about Esperion’s financial health in the comprehensive Pro Research Report.
In other recent news, Esperion Therapeutics reported a significant revenue increase for the fourth quarter of 2024, with total revenue reaching $69.1 million, marking a 114% year-over-year growth. This figure surpassed the forecasted revenue of $63.45 million. The company also reported an earnings per share (EPS) of -$0.11, which was better than the anticipated -$0.14. A key contributor to the revenue surge was a 52% increase in U.S. net product revenue and a 227% rise in collaboration revenue. Additionally, Esperion ended the fiscal year with approximately $145 million in cash, positioning the company well for future investments.
Analysts at JMP reaffirmed their Market Outperform rating and maintained a $4.00 price target for Esperion, highlighting the global growth potential of its bempedoic acid franchises. Despite the positive revenue figures, U.S. net product sales for the quarter were $31.6 million, slightly below JMP’s prediction of $35 million and the consensus estimate of $34.5 million. However, Esperion’s management anticipates that the impact of the Medicare coverage gap on earnings is a one-time event, expecting net revenue to better reflect demand growth in 2025.
The company also reported an increase in its prescriber base and prescription volume, with an 8% rise in new-to-brand prescriptions. More than 25,000 healthcare professionals wrote prescriptions for Esperion’s products in the fourth quarter of 2024. These developments are part of Esperion’s ongoing efforts to expand its market presence, both in the U.S. and internationally, with plans to enter markets in Japan, Israel, and Canada.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.